Registro:

Referencias:

• Koury, M.J., Sawyer, S.T., Brandt, S.J., New insights into erythropoiesis (2002) Curr Opin Hematol, 9, pp. 93-100
• Zhande, R., Karsan, A., Erythropoietin promotes survival of primary human endothelial cells through PI3K-dependent, NF-kB-independent upregulation of Bcl-xL (2007) Am J Physiol, 292, pp. 2467-2474
• Wen, D., Biossel, J.P., Showers, M., Ruch, B.C., Bunn, F., Erythropoietin structure-function relationships. Identification of functionally important domains (1994) J Biol Chem, 269, pp. 22839-22846
• Banks, D.D., The effect of glycosylation on the folding kinetics of erythropoietin (2011) J Mol Biol, 412, pp. 536-550
• Carnot, P., Deflandre, C., Sur l'activite hemopoietique du serum au cors de la regeneration du sang (1906) CR Acad Sci P, 143, pp. 384-386
• Reissmann, K.R., Studies on the mechanism of the erythropoietic stimulation in parabiotic rats during hypoxia (1950) Blood, 5, pp. 372-380
• Erslev, A.J., Lavietes, P.H., Von Wagenen, G., Erythropoietic stimulation induced by anemic serum (1953) Proc Exp Biol Med, 83, pp. 548-550
• Miyake, T., Kung, C.K., Goldwasser, E., Purification of human erythropoietin (1977) J Biol Chem, 252, pp. 5558-5564
• Lin, F.K., Suggs, S., Lin, C.H., Browne, J.K., Smalling, R., Egrie, J.C., Cloning and expression of the human erythropoietin gene (1985) Proc Natl Acad Sci USA, 82, pp. 7580-7584
• Davis, J., Arakawa, T., Strikland, T.W., Yphantis, D.A., Characterization of recombinant human erythropoietin produced in Chinese hamster ovary cells (1987) Biochemistry, 26, pp. 2638-2641
• Eschbach, J.W., Egrie, J.C., Downing, M.R., Browne, J.K., Adamson, J.W., Correction of the anemia of end-stage renal disease with recombinant human erythropoietin. Results of a combined phase i and II clinical trial (1987) New Engl J Med, 316, pp. 73-78
• De Marchi, S., Parisi, M., Ferraccioli, G.F., Erythropoietin and the anemia of chronic diseases (1993) Clin Exp Rheumatol, 11, pp. 429-444
• Bron, D., Meuleman, N., Mascaux, C., Biological basis of anemia (2001) Semin Oncol, 28, pp. 1-6
• Damacco, F., Luccarelli, G., Prete, M., Silvestris, F., The role of the human recombinant erythropoietin alpha in the treatment of chronic anemia in multiple myeloma (2002) Rev Clin Exp Hematol, 1, pp. 32-38
• Reiter, P.D., Rosenberg, A.A., Valuck, R., Novak, K., Effect of short-term erythropoietin therapy in anemic premature infants (2005) J Perinatol, 25, pp. 125-129
• Arndt, U., Kaltwasser, J.P., Gottschalk, R., Hoelzer, D., Möller, B., Correction of iron-deficient erythropoiesis in the treatment of anemia of chronic disease with recombinant human erythropoietin (2005) Ann Hematol, 84, pp. 159-166
• Boehm, M., Riesenhuber, A., Winkelmayer, W.C., Arbeiter, K., Mueller, T., Aufricht, C., Early erythropoietin therapy is associated with improved growth in children with chronic kidney disease (2007) Pediatr Nephrol, 22, pp. 1189-1193
• Jelkmann, W., Molecular biology of erythropoietin (2004) Int Med, 43, pp. 649-659
• Rossert, J., Eckardt, K.-U., Erythropoietin receptors: Their role beyond erythropoiesis (2005) Nephrol Dial Transplant, 20, pp. 1025-1028
• Digicaylioglu, M., Lipton, S., Erythropoietin-mediated neuroprotection involves cross-talk between Jak2 and NF-kappa B signalling cascades (2001) Nature, 412, pp. 641-647
• Sirén, A.L., Fratelli, M., Brines, M., Goemans, C., Casagrande, S., Lewzuk, P., Erythropoietin prevents neuronal apoptosis after cerebral ischemia and metabolic stress (2001) Proc Natl Acad Sci USA, 98, pp. 4044-4049
• Grasso, G., Sfacteria, A., Meli, F., Fodale, V., Buemi, M., Iacopino, D.G., Neuroprotection by erythropoietin administration after experimental traumatic brain injury (2007) Brain Res, 1182, pp. 99-105
• Toba, H., Kojima, Y., Wang, J., Noda, K., Tian, W., Kobara, M., Erythropoietin attenuated vascular dysfunction and inflammation by inhibiting NADPH oxidase-derived superoxide production in nitric oxide synthase-inhibited hypertensive rat aorta (2012) Eur J Pharmacol, 691, pp. 190-197
• Bailey, D.M., Lundby, C., Berg, R.M., Taudorf, S., Rahmouni, H., Gutowski, M., On the antioxidant properties of erythropoietin and its association with the oxidative-nitrosative stress response to hypoxia in humans (2014) Acta Physiol, 212, pp. 175-187
• Wang, L., Di Noguchi, L.C.T., Erythropoietin: A novel versatile player regulating energy metabolism beyond the erythroid system (2014) Int J Biol Sci, 10, pp. 931-939
• Nakao, T., Geddis, A., Fox, N., Kaushansky, PI3K/Akt/FOXO3a pathway contributes to thrombopoietin-induced proliferation of primary megakaryocytes in vitro and in vivo via modulation of p27Kip1 (2008) Cell Cycle, 7, pp. 257-266
• Walrafen, P., Verdier, F., Kadri, Z., Chrétien, S., Lacombe, C., Mayeux, P., Both proteasomes and lysosomes degrade the activated erythropoietin receptor (2005) Blood, 105, pp. 600-608
• Krebs, D., Hilton, D., SOCS: Physiological suppressors of cytokine signalling (2000) J Cell Sci, 113, pp. 2813-2819
• Cohen, J., Oren-Young, L., Klingmüller, U., Neumann, D., Protein tyrosine phosphatase 1B participates in the down-regulation of the erythropoietin receptor signaling (2004) Biochem J, 377, pp. 517-524
• Callero, M., Pérez, G., Vittori, D., Pregi, N., Nesse, A., Modulation of protein tyrosine phosphatase 1B by erythropoietin in UT-7 cell line (2007) Cell Physiol Biochem, 20, pp. 319-328
• Pfeffer, M.A., Burdmann, E.A., Chen, C.Y., Cooper, M.E., De Zeeuw, D., Eckardt, K., A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease (2009) N Engl J Med, 361, pp. 2019-2032
• McKinney, M., Arcasoy, M.O., Erythropoietin for oncology supportive care (2011) Exp Cell Res, 317, pp. 1246-1254
• Drüeke, T., Hyporesponsiveness to recombinant human erythropoietin (2001) Nephrol Dial Transplant, 16, pp. 25-28
• Jelkmann, I., Jelkmann, W., Impact of erythropoietin on intensive care unit patients (2013) Transfus Med Hemother, 40, pp. 310-318
• Okazaki, M., Komatsu, M., Kawaguchi, H., Tsuchiya, K., Nitta, K., Erythropoietin resistance index and the all-cause mortality of chronic hemodialysis patients (2014) Blood Purif, 37, pp. 106-112
• Hung, S.C., Lin, Y.P., Tarng, D.C., Erythropoiesis-stimulating agents in chronic kidney disease: What have we learned in 25 years? (2014) J Formos Med Assoc, 113, pp. 3-10
• Macdougall, I., Cooper, A., Erythropoietin resistance: The role of inflammation and pro-inflammation cytokines (2002) Nephrol Dial Transplant, 17, pp. 39-43
• Zhang, M.-Y., Sun, S.-C., Bell, L., Miller, C., NF-kappa B transcription factors are involved in normal erythropoiesis (1998) Blood, 91, pp. 4136-4144
• Akagi, S., Ichikawa, H., Okada, T., Sarai, A., Sugimoto, T., Morimoto, H., The critical role of SRC homology domain 2-containing tyrosine phosphatase-1 in recombinant human erythropoietin hyporesponsive anemia in chronic hemodialysis patients (2004) J Am Soc Nephrol, 15, pp. 3215-3224
• Zabolotny, J.M., Kim, Y.B., Silencing insulin resistance through SIRT1 (2007) Cell Metab, 6, pp. 247-249
• Van Der Putten, K., Braam, B., Jie, K.E., Gaillard, C.A., Mechanisms of disease: Erythropoietin resistance in patients with both heart and kidney failure (2008) Nat Clin Pract Nephrol, 4, pp. 47-57
• Dagvadorj, J., Naiki, Y., Tumurkhuu, G., Noman, A.S., Iftakhar-E-Khuda, I., Komatsu, T., Tumor necrosis factor-alpha augments lipopolysaccharide-induced suppressor of cytokine signalling 3 (SOCS-3) protein expression by preventing the degradation (2010) Immunology, 129, pp. 97-104
• Callero, M., (2010) Proteína Tirosina Fosfatasa 1B en la VÍa de Señalización de la Eritropoyetina, , Tesis Doctoral, Universidad de Buenos Aires
• Coleman, T., Westenfelder, C., Tögel, F., Yang, Y., Hu, Z., Swenson, L.A., Cytoprotective doses of erythropoietin or carbamylated erythropoietin have markedly different procoagulant and vasoactive activities (2006) Proc Natl Acad Sci USA, 103, pp. 5965-5970
• Wagner, M., Alam, A., Zimmermann, J., Rauh, K., Koljaja-Batzner, A., Raff, U., Endogenous erythropoietin and the association with inflammation and mortality in diabetic chronic kidney disease (2011) Clin J Am Soc Nephrol, 6, pp. 1573-1579
• Singh, A.K., Is there a deleterious effect of erythropoietin in end-stage renal disease? (2011) Kidney Int, 80, pp. 569-571
• Gao, D., Ning, N., Niu, X., Dang, Y., Dong, X., Wei, J., Erythropoietin treatment in patients with acute myocardial infarction: A meta-analysis of randomized controlled trials (2012) Am Heart J, 164, pp. 715-727
• Beleslin-Cokic, B., Cokic, V., Yu, X., Weksler, B., Schechter, A., Noguchi, C., Erythropoietin and hypoxia stimulate erythropoietin receptor and nitric oxide production by endothelial cells (2004) Blood, 104, pp. 2073-2080
• Garimella, P., Katz, R., Patel, K., Kritchevsky, S., Parikh, Ch., Ix, J., Association of serum erythropoietin with cardiovascular events, kidney function decline, and mortality: The health aging and body composition study (2016) Circ Heart Fail, 9, p. e002124. , 10.1161
• Grote Beverborg, N., Van Der Wal, H., Klip, I., Voors, A., De Boer, R., Van Gilst, W., High serum erythropoietin levels are related to heart failure development in subjects from the general population with albuminuria: Data from PREVEND (2016) Eur J Heart Fail, 18, pp. 814-821
• Brines, M., Cerami, A., Emerging biological roles for erythropoietin in the nervous system (2005) Natl Rev Neusci, 6, pp. 484-494
• Erbayraktar, S., Grasso, G., Sfacteria, A., Xie, Q.-W., Coleman, T., Kreilgaard, M., Asialoerythropoietin is a nonerythropoietic cytokine with broad neuroprotective activity in vivo (2003) Proc Ntl Acad Sci USA, 100, pp. 6741-6746
• Leist, M., Ghezzi, P., Grasso, G., Bianchi, R., Villa, P., Fratelli, M., Derivatives of Erythropoietin that are tissue protective but not erythropoietic (2004) Science, 305, pp. 239-242
• Mun, K.-Ch., Golper, T.A., Impaired biological activity of erythropoietin by cyanate carbamylation (2000) Blood Purif, 18, pp. 13-17
• Park, K.-D., Mun, K.-C., Chang, E.-J., Park, S.-B., Kim, H.-C., Inhibition of erythropoietin activity by cyanate (2004) Scand J Urol Nephrol, 38, pp. 69-72
• Fantacci, M., Bianciardi, P., Caretti, A., Coleman, T., Cerami, A., Brines, M., Carbamylated erythropoietin ameliorates the metabolic stress in vivo by severe chronic hypoxia (2006) Proc Natl Acad Sci USA, 103, pp. 17531-17536
• Erbayraktar, S., De Lanerolle, N., De Lotbinière, A., Knisely, J.P., Erbayraktar, Z., Yilmaz, O., Carbamylated erythropoietin reduces radiosurgically-induced brain injury (2006) Mol Med, 12, pp. 74-80
• Tang, Z., Sun, X., Shi, Q., Wang, X., Xie, Y., Huo, G., Beneficial effects of carbamylated erythropoietin against oxygen- glucose deprivation/reperfusion-induced astrocyte swelling (2012) Neurosci Letters, 530, pp. 23-28
• Chamorro, M.E., Wenker, S., Vota, D., Vittori, D., Nesse, A., Signaling pathways of cell proliferation are involved in the differential effect of erythropoietin and its carbamylated derivative (2013) Biochim Biophys Acta-Mol Cell Res, 1833, pp. 1960-1968
• Chamorro, M.E., Maltaneri, R., Vittori, D., Nesse, A., Protein tyrosine phosphatase 1B (PTP1B) is involved in the defective erythropoietic function of carbamylated erythropoietin (2015) Int J Biochem Cell Biol, 61, pp. 63-71
• Chen, J., Yang, Z., Zhang, X., Carbamylated erythropoietin: A prospective drug candidate for neuroprotection (2015) Biochem Insights, 8, pp. 25-29
• Jubisnsky, P.T., Krijanovski, O.I., Nathan, D.G., Tavernier, J., Sieff, C.A., The β chain of the Interleukin-3 Receptor functionally associates with the erythropoietin receptor (1997) Blood, 90, pp. 1867-1873
• Brines, M., Grasso, G., Fiordaliso, F., Sfacteria, A., Ghezzi, P., Fratelli, M., Erythropoietin mediates tissue protection through an erythropoietin and common beta-subunit heteroreceptor (2004) Proc Natl Acad Sci USA, 101, pp. 14907-14912
• Skibeli, V., Nissen-Lie, G., Torjesen, P., Sugar profiling proves that human serum erythropoietin differs from recombinant human erythropoietin (2001) Blood, 98, pp. 3626-3634
• Darling, R.J., Kuchibhotla, U., Glaesner, W., Micanovic, R., Witcher, D.R., Beals, J.M., Glycosylation of erythropoietin affects receptor binding kinetics: Role of electrostatic interactions (2002) Biochemistry, 41, pp. 14524-14531
• Sirén, A.L., Fasshauer, T., Bartels, C., Ehrenreich, H., Therapeutic potential of erythropoietin and its structural or functional variants in the nervous system (2009) Neurotherapeutics, 6, pp. 108-127
• Macdougall, I.C., Optimizing erythropoietin therapy (1999) Curr Opin Hematol, 6, pp. 121-126
• Macdougall, I.C., CERA (Continuous Erythropoietin Receptor Activator): A new erythropoiesis-stimulating agent for the treatment of anemia (2005) Curr Hematol Rep, 4, pp. 436-440
• López-Gómez, J.M., Abad, S., Vega, A., Nuevas expectativas en el tratamiento de la anemia en la enfermedad renal crónica (2016) Nefrología (España), 36, pp. 232-236
• Schmid, H., Jelkmann, W., Investigational therapies for renal disease-induced anemia (2016) Expert Opin Invest Drugs

Citas:

---------- APA ----------

---------- CHICAGO ----------

---------- MLA ----------

---------- VANCOUVER ----------